Welcome to our dedicated page for Leap Therapeutic SEC filings (Ticker: LPTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings archive for Leap Therapeutics, Inc. under the historical ticker LPTX provides official documentation of the company’s evolution into Cypherpunk Technologies Inc. and its dual focus on oncology therapeutics and a Zcash-centered digital asset treasury strategy. Forms 8-K detail key events such as the October 2025 private placement led by Winklevoss Capital, adoption of the digital asset treasury strategy, and subsequent name change to Cypherpunk Technologies Inc., along with the planned shift to trading under the symbol CYPH on the Nasdaq Capital Market.
Regulatory reports describe capital markets transactions, including the issuance of common stock, pre-funded warrants, and common warrants, registration rights agreements, and a controlled equity offering sales agreement that allows at-the-market issuances of common stock. Other filings outline Nasdaq bid price deficiency notices, the grant of an additional compliance period, and the company’s consideration of a reverse stock split to address listing standards.
Filings also cover corporate governance and compensation, such as consulting and employment agreements with new digital asset–focused leadership, equity incentive awards in the form of restricted stock units, and board expansion and nomination rights for the lead investor. The definitive proxy statement for a special meeting explains proposals to increase authorized shares, authorize a reverse stock split range, adopt a new equity incentive plan, and approve additional share issuance under the private placement warrants.
For those analyzing the oncology side of the business, 8-Ks and related exhibits reference the wind-down of the DeFianCe clinical trial, reductions in research and development activities, and the exploration of strategic alternatives for sirexatamab and FL-501. On Stock Titan, these filings are paired with AI-powered summaries that help interpret complex agreements, capital structure changes, and disclosure language, while real-time updates from EDGAR ensure that new 10-K, 10-Q, 8-K, and proxy materials for the issuer formerly known as Leap Therapeutics are quickly accessible.
Leap Therapeutics, Inc. reported that it has entered into a private placement and adopted a new digital asset treasury strategy. The company plans to maintain its existing biopharmaceutical business while also pursuing this digital asset approach to managing part of its treasury. These developments were first described in a press release dated October 6, 2025, which is attached as an exhibit to the report.
Leap Therapeutics, Inc. received an additional 180-day grace period from Nasdaq, until March 9, 2026, to regain compliance with the Nasdaq Capital Market’s $1.00 minimum bid price requirement for its common stock. The extension was granted because the company met all other initial listing standards, including the market value of publicly held shares.
During this second compliance period, Leap Therapeutics could still be delisted if it fails to satisfy other Nasdaq listing rules. The company plans to monitor its share price and may consider a reverse stock split to restore compliance, but there is no assurance it will succeed or avoid eventual delisting.
Schedule 13G/A disclosure for Leap Therapeutics, Inc. (LPTX) This filing is a joint Schedule 13G/A by Samsara BioCapital, L.P., Samsara BioCapital GP, LLC and Srinivas Akkaraju reporting that, as of June 30, 2025, each Reporting Person beneficially owns 0 shares (0.0%) of Leap Therapeutics common stock (CUSIP 52187K200). The Reporting Persons state they are not a "group" and provide a Palo Alto business address for the filer. The filing incorporates a prior Joint Filing Statement by reference and is signed by Srinivas Akkaraju on behalf of the entities on August 14, 2025. The statement certifies the securities were not acquired to influence control of the issuer.
Leap Therapeutics, Inc. (LPTX) filed a Form 8-K reporting an item related to Results of Operations and Financial Condition and furnished a press release as an exhibit. The filing identifies Item 9.01 (Financial Statements and Exhibits) and lists Exhibit 99.1 as a press release dated August 14, 2025. The disclosure is signed by Douglas E. Onsi, Chief Executive Officer and President. The document does not include financial statements, earnings figures, transaction details, or other substantive operational data within the provided text.
Leap Therapeutics reported a difficult quarter marked by clinical progress on its lead asset but acute financial stress. Updated DeFianCe Part B data showed sirexatamab (DKN-01) produced a statistically significant benefit on overall response rate and progression-free survival in colorectal cancer patients with high DKK1, no prior anti‑VEGF therapy, or liver metastasis, with final study results being prepared for conference presentation.
Financially, the company had $18.13 million in cash and cash equivalents and $20.04 million total assets as of June 30, 2025, and reported a $32.08 million net loss for the six months ended June 30, 2025, leaving an accumulated deficit of $499.45 million. Management disclosed substantial doubt about the company’s ability to continue as a going concern, implemented a workforce reduction of approximately 75% and recorded $4.53 million of restructuring charges, and engaged Raymond James to explore strategic alternatives.